A new international study has revealed a potentially game-changing approach to managing heart attack survivors, promising to save thousands of lives and ease the burden on health services across the globe.

The research, conducted by scientists from Sweden’s Lund University and Imperial College London, suggests that adding the cholesterol-lowering drug ezetimibe to statin therapy soon after a heart attack could dramatically improve patient outcomes. This early intervention, the researchers say, might prevent a significant number of repeat heart attacks that currently lead to unnecessary suffering, hospital admissions, and premature deaths.

Heart disease remains the world’s leading killer, outstripping all other causes of mortality. In 2022, ischemic heart disease (heart attack) was the leading cause of death in Malaysia, accounting for 17% of all fatalities. Specifically, there were 20,322 deaths attributed to ischemic heart disease, which is 16.1% of total medically confirmed deaths. A significant portion, approximately 35.2%, of these heart attack fatalities occurred in individuals under the age of 60. Survivors of a heart attack face their highest risk of another cardiovascular event in the first twelve months, a period during which their blood vessels are especially vulnerable.

Current guidelines recommend that patients receive high-potency statins as soon as possible after a heart attack to reduce so-called “bad” cholesterol (LDL cholesterol) and stabilise the blood vessels. Statins have long been a cornerstone of cardiovascular care. However, mounting evidence shows that many patients simply do not reach the cholesterol targets that would best protect them from future heart attacks or strokes when using statins alone. This is where ezetimibe enters the conversation—an add-on medication that blocks cholesterol absorption in the gut, working alongside statins to drive cholesterol levels even lower.

Yet, despite its proven benefits and low cost, ezetimibe is not routinely prescribed at the outset. Guidelines typically favour a slow, stepwise escalation: first statins, then ezetimibe if cholesterol remains high during follow-up appointments. In practice, this process is fraught with delays, missed opportunities, and patients falling through the cracks. According to Swedish and British researchers, this cautious approach may be costing lives.

The team turned to Sweden’s comprehensive national registry, analysing data from 36,000 adults who experienced a heart attack between 2015 and 2022. They categorised patients into groups: those started on ezetimibe within 12 weeks of their heart attack (in addition to statins), those who received it later (between 13 weeks and 16 months), and those who never received ezetimibe at all. Using sophisticated statistical modelling to emulate the rigour of a clinical trial, the researchers found a clear pattern: patients who began combination therapy early had notably better outcomes than those treated later or not at all.

The numbers are compelling. Early use of ezetimibe, alongside statins, was associated with a lower risk of major cardiovascular events—repeat heart attacks, strokes, and death. If every eligible patient in the UK received this combination treatment promptly after their initial heart attack, researchers estimate that over 5,000 repeat heart attacks could be prevented over a decade. Globally, the impact would be even more profound.

Why does early intervention work so well? After a heart attack, arteries are particularly susceptible to further blockages as the vessel walls are inflamed and prone to clot formation. Rapidly lowering LDL cholesterol stabilises these vulnerable areas, reducing the chance of another life-threatening event. Waiting for months or years to intensify cholesterol treatment, as is often done under current protocols, misses this critical window.

Experts point out that ezetimibe is widely available and inexpensive—costing around £350 per patient per year in the UK—making it a highly cost-effective strategy compared to treating recurrent heart attacks and their complications. In addition, ezetimibe’s safety profile is reassuring; side effects are rare and generally mild.

Despite this, two main barriers stand in the way of wider adoption. Firstly, current guidelines do not universally recommend starting both drugs at once unless cholesterol targets are not met after several months on statins alone. Secondly, clinicians sometimes hesitate to prescribe more than one cholesterol-lowering drug at the outset due to concerns about side effects or overmedication. However, this new research challenges those assumptions and argues for a rethink.

Further strengthening their case, Swedish hospitals that have adopted an algorithm recommending immediate combination therapy report impressive results. Twice as many patients reach their cholesterol targets within two months compared with previous approaches. These encouraging outcomes have led several other hospitals in Sweden—and some abroad—to follow suit.

The study’s lead authors believe it is time for a global review of treatment pathways after myocardial infarction (the medical term for a heart attack). The evidence now points towards early action as crucial: start with both statins and ezetimibe from day one rather than waiting for cholesterol levels to remain stubbornly high.

The potential benefits extend beyond survival statistics. Preventing a second heart attack also means sparing patients from further hospital stays, invasive procedures, anxiety, and disability—not to mention easing strain on already overstretched healthcare systems.

Published in the prestigious Journal of the American College of Cardiology (JACC), the findings have already sparked interest among policy-makers and clinicians eager for practical ways to improve cardiac care without breaking the bank.

So what needs to change? According to experts involved in the research, national and international guidelines must evolve to reflect this new evidence. Hospitals should consider adopting algorithms that prompt doctors to prescribe combination therapy earlier for patients recovering from heart attack. Public health authorities might also launch awareness campaigns targeting both doctors and patients about the proven benefits of early dual therapy.

Some resistance is inevitable; medical practice rarely shifts overnight. However, history shows that when robust data supports a simple intervention with clear benefits and minimal risks, widespread change can follow swiftly. The success of statins themselves was once met with scepticism before they became standard care.

It is important to note that not every patient will be suitable for combination therapy; individual medical histories and tolerances must still guide care decisions. Nonetheless, for the majority recovering from a first heart attack, this approach appears both safe and highly effective.

Looking ahead, further research may explore whether even more powerful combinations or novel lipid-lowering agents could deliver greater protection still. For now though, experts are urging healthcare providers not to wait—thousands of lives could be saved simply by making better use of tools already on pharmacy shelves.

Early addition of ezetimibe to statin therapy after a heart attack could herald a new era in secondary prevention of cardiovascular disease. The evidence is robust; the costs are moderate; the risks are low; and the stakes—measured in lives saved and suffering avoided—are exceptionally high.

As this latest study makes clear: sometimes progress lies not in new inventions but in using what we already have, more wisely and more quickly. For heart attack survivors and their families, that could mean more years enjoyed together—a goal worth striving for.